Largest Global Supplier of Paclitaxel API via PCF®
Pacilitaxel (sold under trade name Taxol® by Bristol-Myers Squibb) is a very effective plant-derived chemotherapy drug used to treat breast, ovarian, lung, bladder, prostate, melanoma, esophageal, as well as other types of solid tumor cancers. It has also been used to treat Kaposi’s sarcoma.
Formula: C47 H51 NO14
CAS Number: 33069-62-4
Chemical Name: [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,1-2α,12aα,12bα]]-β-(Benzoylamino)-α-hydroxybenzenepropanoic acid 6, 12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a-,12b-dodecahydro-4, 11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz [1,2-b]oxet -9-yl ester
Phyton has a nearly 20-year track record of producing API-grade Paclitaxel on a large scale. Our plant cell fermentation facility in Germany has an annual capacity of nearly 1,000 kg of crude Paclitaxel.
We are the only large-scale Paclitaxel supplier in the world that controls the entire upstream and downstream production process internally under strict GMP conditions. These controls, along with our scale, bring our customers North American/European quality and reliability at competitive prices.
Our Paclitaxel is produced naturally by cells cultured under cGMP conditions, providing a safe and dependable supply of finished API product that meets USP and EP standards.
Because our Paclitaxel is produced entirely within a contained environment, it is not subject to changes in the supply of biomass or 10-DAB resulting from climate, seasonality, price competition, disease, or political restrictions. We have full control of our supply chain.
Phyton produces Paclitaxel using our proprietary Plant Cell Fermentation Technology (PCF®), an environmentally-friendly process that produces natural pharmaceutical ingredients directly from plant cells. Our Paclitaxel is a 100% natural and GMO-free product derived from a proprietary cell line developed using plant cells of the species Taxus chinensis v. marei.
With PCF®, Phyton can produce Paclitaxel without the harvest of wild or plantation biomass, or semi-synthesis from 10-deaceytlbaccatin III (10-DAB). The supply of Paclitaxel and the intermediate 10-DAB extracted from biomass is vulnerable to harvesting and supply issues related to weather, disease and the application of pesticides. Further, the extraction of these compounds from biomass is extremely solvent intensive in comparison to Phyton’s proprietary PCF® process. Read our Green Chemistry case study on Paclitaxel.